Attached files
file | filename |
---|---|
S-1MEF - S-1MEF - ALX ONCOLOGY HOLDINGS INC | d64293ds1mef.htm |
EX-23.2 - EX-23.2 - ALX ONCOLOGY HOLDINGS INC | d64293dex232.htm |
EX-5.1 - EX-5.1 - ALX ONCOLOGY HOLDINGS INC | d64293dex51.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
ALX Oncology Holdings Inc.:
We consent to the use of our report dated June 12, 2020, except for the retroactive effect of the reverse stock split as described under the heading Reverse Stock Split in Note 4, which is as of July 13, 2020, with respect to the balance sheet of ALX Oncology Holdings Inc. as of April 1, 2020 (inception), and the related notes, in the registration statement (No. 333-239490) on Form S-1, included therein and incorporated by reference herein, and to the reference to our firm under the heading Experts.
/s/ KPMG LLP
San Francisco, California
July 16, 2020